At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 8, 2026 at 06:31 ET
Artiva reported Q1 2026 GAAP EPS of -$0.95, missing the Street consensus of -$0.84 by 13.1%, while revenue remained $0. The net loss widened to $23.5M from $20.3M a year ago. However, the stock is likely to move on the positive clinical catalyst: FDA alignment on a single Phase 3 registrational trial for AlloNK in refractory RA, with 71% ACR50 response at six months in initial data, supporting a potential path to market.
- Q1 2026 GAAP EPS -$0.95 vs consensus -$0.84 (13.1% miss)
- Net loss $23.5M vs $20.3M YoY, driven by higher R&D spend ($19.3M vs $17.1M)
- Cash runway into Q2 2027 with $86.8M in cash and investments
- FDA alignment on single Phase 3 registrational trial for AlloNK in refractory RA; trial initiation H2 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access